Tissue-specific Role of CX3CR1 Expressing Immune Cells and Their Relationships with Human Disease

키워드

참고문헌 (105)

1. Kim KW, "In vivo structure", function and expression analysis of the CX3C chemokine fractalkine, 2011, pp.118, e156~e167
2. Imai T, "Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion", Cell, 91, pp.521~530 (1997)[DOI]
3. Hundhausen C, "The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion", Blood, 102, pp.1186~1195 (2003)[DOI]
4. Garton KJ, "Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1)", J Biol Chem, 276, pp.37993~38001 (2001)
5. Geissmann F, "Blood monocytes consist of two principal subsets with distinct migratory properties", Immunity, 19, pp.71~82 (2003)[DOI]
6. Bain CC, "Intestinal macrophages - specialised adaptation to a unique environment", Eur J Immunol, 41, pp.2494~2498 (2011)[DOI]
7. Hamon P, "CX3CR1-dependent endothelial margination modulates Ly6Chigh monocyte systemic deployment upon inflammation in mice", Blood, 129, pp.1296~1307 (2017)[DOI]
8. Liu Z, "CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-<TEX>${\beta}$<", TEX> phagocytosis, 2010, pp.30, 17091~17101
9. Fuhrmann M, "Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease", Nat Neurosci, 13, pp.411~413 (2010)[DOI]
10. Jacquelin S, "CX3CR1 reduces Ly6Chigh-monocyte motility within and release from the bone marrow after chemotherapy in mice", Blood, 122, pp.674~683 (2013)[DOI]
11. Hoshino A, "Roles of chemokine receptor CX3CR1 in maintaining murine bone homeostasis through the regulation of both osteoblasts and osteoclasts", J Cell Sci, 126, pp.1032~1045 (2013)[DOI]
12. Li S, "CD8+ T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura", Br J Haematol, 139, pp.605~611 (2007)[DOI]
13. Olsson B, "Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1", Blood, 112, pp.1078~1084 (2008)[DOI]
14. Hurley A, "Enhanced effector function of CD8(+) T cells from healthy controls and HIV-infected patients occurs through thrombin activation of protease-activated receptor 1", J Infect Dis, 207, pp.638~650 (2013)[DOI]
15. Apostolakis S, "Chemokines and atherosclerosis: focus on the CX3CL1", CX3CR1 pathway, 2013, pp.34, 1251~1256
16. Wu Z, "CX3CR1(+) B cells show immune suppressor properties", J Biol Chem, 289, pp.22630~22635 (2014)[DOI]
17. Zhivaki D, "Respiratory syncytial virus infects regulatory B cells in human neonates via chemokine receptor CX3CR1 and promotes lung disease severity", Immunity, 46, pp.301~314 (2017)[DOI]
18. Sciume G, "CX3CR1 expression defines 2 KLRG1+ mouse NK-cell subsets with distinct functional properties and positioning in the bone marrow", Blood, 117, pp.4467~4475 (2011)[DOI]
19. Ponzetta A, "CX3CR1 regulates the maintenance of KLRG1+ NK cells into the bone marrow by promoting their entry into circulation", J Immunol, 191, pp.5684~5694 (2013)[DOI]
20. Hamann I, "Analyses of phenotypic and functional characteristics of CX3CR1-expressing natural killer cells", Immunology, 133, pp.62~73 (2011)[DOI]
21. Yano R, "Recruitment of CD16+ monocytes into synovial tissues is mediated by fractalkine and CX3CR1 in rheumatoid arthritis patients", Acta Med Okayama, 61, pp.89~98 (2007)
22. Sawai H, "T cell costimulation by fractalkine-expressing synoviocytes in rheumatoid arthritis", Arthritis Rheum, 52, pp.1392~1401 (2005)[DOI]
23. Blaschke S, "Proinflammatory role of fractalkine (CX3CL1) in rheumatoid arthritis", J Rheumatol, 30, pp.1918~1927 (2003)
24. Nanki T, "Inhibition of fractalkine ameliorates murine collagen-induced arthritis", J Immunol, 173, pp.7010~7016 (2004)[DOI]
25. Tarrant TK, "Decreased Th17 and antigen-specific humoral responses in <TEX>$CX_{3}$<", TEX> CR1-deficient mice in the collagen-induced arthritis model, 2012, pp.64, 1379~1387
26. Tanaka Y, "Safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in a first-in-patient phase 1", 2 study in rheumatoid arthritis, 2015, pp.67, 3960~3962
27. Ryu J, "Activation of fractalkine", CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A, Cardiovasc Res, pp.2008, 78[DOI]
28. Moreno PR, "Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture", Circulation, 90, pp.775~778 (1994)[DOI]
29. Arras M, "Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb", J Clin Invest, 101, pp.40~50 (1998)[DOI]
30. Ren J, "Elevated expression of CX3C chemokine receptor 1 mediates recruitment of T cells into bone marrow of patients with acquired aplastic anaemia", J Intern Med, 276, pp.512~524 (2014)[DOI]
31. Moore KJ, "Macrophages in atherosclerosis: a dynamic balance", Nat Rev Immunol, 13, pp.709~721 (2013)[DOI]
32. Swirski FK, "Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata", J Clin Invest, 117, pp.195~205 (2007)[DOI]
33. Landsman L, "CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival", Blood, 113, pp.963~972 (2009)[DOI]
34. Bjerkeli V, "Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener's granulomatosis--possible role in vascular inflammation", Rheumatology (Oxford), 46, pp.1422~1427 (2007)[DOI]
35. Csernok E, "Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation", Arthritis Rheum, 42, pp.742~750 (1999)[DOI]
36. Croitoru-Lamoury J, "Expression of chemokines and their receptors in human and simian astrocytes: evidence for a central role of TNF alpha and IFN gamma in CXCR4 and CCR5 modulation", Glia, 41, pp.354~370 (2003)[DOI]
37. Sellner S, "Microglial CX3CR1 promotes adult neurogenesis by inhibiting Sirt 1", p65 signaling independent of CX3CL1, 2016, pp.4, 102~
38. Sheridan GK, "Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage", Open Biol, 3, pp.130181~ (2013)[DOI]
39. Bachstetter AD, "Fractalkine and CX 3 CR1 regulate hippocampal neurogenesis in adult and aged rats", Neurobiol Aging, 32, pp.2030~2044 (2011)[DOI]
40. McMillin M, "Fractalkine suppression during hepatic encephalopathy promotes neuroinflammation in mice", J Neuroinflammation, 13, pp.198~ (2016)[DOI]
41. Yan SD, "RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease", Nature, 382, pp.685~691 (1996)[DOI]
42. Dworzak J, "Neuronal Cx3cr1 deficiency protects against amyloid <TEX>${\beta}$<", TEX>-induced neurotoxicity, 2015, pp.10, e0127730~
43. Cherry JD, "Arginase 1+ microglia reduce <TEX>$A{\beta}$<", TEX> plaque deposition during IL-<TEX>$1{\beta}$<, J Neuroinflammation, pp.2015, 12[DOI]
44. Asai H, "Depletion of microglia and inhibition of exosome synthesis halt tau propagation", Nat Neurosci, 18, pp.1584~1593 (2015)[DOI]
45. Sandra M. Cardona, "Disruption of Fractalkine Signaling Leads to Microglial Activation and Neuronal Damage in the Diabetic Retina", ASN Neuro, 7(5), pp.175909141560820~ (2015), SAGE Publications[DOI]
46. Nash KR, "Fractalkine over expression suppresses <TEX>${\alpha}$<", TEX>-synuclein-mediated neurodegeneration, 2015, pp.23, 17~23
47. Kigerl KA, "Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord", J Neurosci, 29, pp.13435~13444 (2009)[DOI]
48. Tang Z, "CX3CR1 deficiency suppresses activation and neurotoxicity of microglia", macrophage in experimental ischemic stroke, 2014, pp.11, 26~
49. Zhang Y, "Fractalkine promotes chemotaxis of bone marrow-derived mesenchymal stem cells towards ischemic brain lesions through Jak2 signaling and cytoskeletal reorganization", FEBS J, 282, pp.891~903 (2015)[DOI]
50. Liu Y, "CX3CL1", CX3CR1-mediated microglia activation plays a detrimental role in ischemic mice brain via p38MAPK, J Cereb Blood Flow Metab, pp.2015, 35[DOI]
51. Hansen CN, "Elevated MMP-9 in the lumbar cord early after thoracic spinal cord injury impedes motor relearning in mice", J Neurosci, 33, pp.13101~13111 (2013)[DOI]
52. Donnelly DJ, "Deficient CX3CR1 signaling promotes recovery after mouse spinal cord injury by limiting the recruitment and activation of Ly6Clo", iNOS+ macrophages, 2011, pp.31, 9910~9922
53. Garcia JA, "Regulation of adaptive immunity by the fractalkine receptor during autoimmune inflammation", J Immunol, 191, pp.1063~1072 (2013)[DOI]
54. Holgate ST, "Treatment strategies for allergy and asthma", Nat Rev Immunol, 8, pp.218~230 (2008)[DOI]
55. Rimaniol AC, "The CX3C chemokine fractalkine in allergic asthma and rhinitis", J Allergy Clin Immunol, 112, pp.1139~1146 (2003)[DOI]
56. Mionnet C, "CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung", Nat Med, 16, pp.1305~1312 (2010)[DOI]
57. Hogg JC, "The nature of small-airway obstruction in chronic obstructive pulmonary disease", N Engl J Med, 350, pp.2645~2653 (2004)[DOI]
58. Ning W, "Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease", Proc Natl Acad Sci U S A, 101, pp.14895~14900 (2004)[DOI]
59. McComb JG, "CX3CL1 up-regulation is associated with recruitment of CX3CR1+ mononuclear phagocytes and T lymphocytes in the lungs during cigarette smoke-induced emphysema", Am J Pathol, 173, pp.949~961 (2008)[DOI]
60. Bonduelle O, "Cutting edge: Protective effect of CX3CR1+ dendritic cells in a vaccinia virus pulmonary infection model", J Immunol, 188, pp.952~956 (2012)[DOI]
61. Jakubzick C, "Blood monocyte subsets differentially give rise to CD103+ and CD103- pulmonary dendritic cell populations", J Immunol, 180, pp.3019~3027 (2008)[DOI]
62. Hall JD, "The impact of chemokine receptor CX3CR1 deficiency during respiratory infections with Mycobacterium tuberculosis or Francisella tularensis", Clin Exp Immunol, 156, pp.278~284 (2009)[DOI]
63. Cardona AE, "Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues", Blood, 112, pp.256~263 (2008)[DOI]
64. Archer S, "Primary pulmonary hypertension: a vascular biology and translational research Work in progress", Circulation, 102, pp.2781~2791 (2000)[DOI]
65. Balabanian K, "CX(3)C chemokine fractalkine in pulmonary arterial hypertension", Am J Respir Crit Care Med, 165, pp.1419~1425 (2002)[DOI]
66. Amsellem V, "Roles for the CX3CL1", CX3CR1 and CCL2, Am J Respir Cell Mol Biol, pp.2017, 56[DOI]
67. Dorfmuller P, "Inflammation in pulmonary arterial hypertension", Eur Respir J, 22, pp.358~363 (2003)[DOI]
68. Ancuta P, "Fractalkine preferentially mediates arrest and migration of CD16+ monocytes", J Exp Med, 197, pp.1701~1707 (2003)[DOI]
69. Crispe IN, "The liver as a lymphoid organ", Annu Rev Immunol, 27, pp.147~163 (2009)[DOI]
70. Sasaki M, "Chemokine-chemokine receptor CCL2-CCR2 and CX3CL1-CX3CR1 axis may play a role in the aggravated inflammation in primary biliary cirrhosis", Dig Dis Sci, 59, pp.358~364 (2014)[DOI]
71. Efsen E, "Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans", J Hepatol, 37, pp.39~47 (2002)[DOI]
72. Wasmuth HE, "The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection", J Hepatol, 48, pp.208~215 (2008)[DOI]
73. Karlmark KR, "The fractalkine receptor <TEX>$CX_{3}$<", TEX> CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes, 2010, pp.52, 1769~1782
74. Aoyama T, "CX3CL1-CX3CR1 interaction prevents carbon tetrachloride-induced liver inflammation and fibrosis in mice", Hepatology, 52, pp.1390~1400 (2010)[DOI]
75. Sutti S, "CX3CR1 modulates the anti-inflammatory activity of hepatic dendritic cells in response to acute liver injury", Clin Sci (Lond), 131, pp.2289~2301 (2017)[DOI]
76. Harada K, "In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset", Hepatology, 25, pp.791~796 (1997)[DOI]
77. Shimoda S, "CX3CL1 (fractalkine): a signpost for biliary inflammation in primary biliary cirrhosis", Hepatology, 51, pp.567~575 (2010)[DOI]
78. Joeris T, "Diversity and functions of intestinal mononuclear phagocytes", Mucosal Immunol, 10, pp.845~864 (2017)[DOI]
79. Gross M, "Guardians of the gut - murine intestinal macrophages and dendritic cells", Front Immunol, 6, pp.254~ (2015)
80. Niess JH, "CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance", Science, 307, pp.254~258 (2005)[DOI]
81. Ferretti E, "Role of fractalkine", CX3CL1 and its receptor in the pathogenesis of inflammatory and malignant diseases with emphasis on B cell malignancies, 2014, pp.2014, 480941~
82. Bain CC, "Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors", Mucosal Immunol, 6, pp.498~510 (2013)[DOI]
83. Rivollier A, "Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to inflammatory dendritic cells in the colon", J Exp Med, 209, pp.139~155 (2012)[DOI]
84. Zigmond E, "Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells", Immunity, 37, pp.1076~1090 (2012)[DOI]
85. Bain CC, "Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice", Nat Immunol, 15, pp.929~937 (2014)[DOI]
86. Hadis U, "Intestinal tolerance requires gut homing and expansion of FoxP3+ regulatory T cells in the lamina propria", Immunity, 34, pp.237~246 (2011)[DOI]
87. Chang SY, "Circulatory antigen processing by mucosal dendritic cells controls CD8(+) T cell activation", Immunity, 38, pp.153~165 (2013)[DOI]
88. Panea C, "Intestinal monocyte-derived macrophages control commensal-specific th17 responses", Cell Reports, 12, pp.1314~1324 (2015)[DOI]
89. Schneider KM, "CX3CR1 is a gatekeeper for intestinal barrier integrity in mice: Limiting steatohepatitis by maintaining intestinal homeostasis", Hepatology, 62, pp.1405~1416 (2015)
90. Kaser A, "Inflammatory bowel disease", Annu Rev Immunol, 28, pp.573~621 (2010)[DOI]
91. Kobayashi T, "Exclusive increase of CX3CR1+CD28-CD4+ T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes", Inflamm Bowel Dis, 13, pp.837~846 (2007)[DOI]
92. Kostadinova FI, "Crucial involvement of the CX3CR1-CX3CL1 axis in dextran sulfate sodium-mediated acute colitis in mice", J Leukoc Biol, 88, pp.133~143 (2010)[DOI]
93. Kayama H, "Intestinal CX3C chemokine receptor 1(high) (CX3CR1(high)) myeloid cells prevent T-cell-dependent colitis", Proc Natl Acad Sci U S A, 109, pp.5010~5015 (2012)[DOI]
94. Medina-Contreras O, "CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice", J Clin Invest, 121, pp.4787~4795 (2011)[DOI]
95. Mortha A, "Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis", Science, 343, pp.1249288~ (2014)[DOI]
96. Xin H, "Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells", Eur J Immunol, 35, pp.1371~1380 (2005)[DOI]
97. Guo J, "Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells", Int J Cancer, 103, pp.212~220 (2003)[DOI]
98. Lavergne E, "Fractalkine mediates natural killer-dependent antitumor responses in vivo", Cancer Res, 63, pp.7468~7474 (2003)
99. Park MH, "High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma", J Surg Oncol, 106, pp.386~392 (2012)[DOI]
100. Zhang X, "Involvement of interaction between Fractalkine and CX3CR1 in cytotoxicity of natural killer cells against tumor cells", Oncol Rep, 15, pp.485~488 (2006)
101. Yu YR, "Defective antitumor responses in CX3CR1-deficient mice", Int J Cancer, 121, pp.316~322 (2007)[DOI]
102. Gao JQ, "Antitumor effect by interleukin-11 receptor alpha-locus chemokine", CCL27, introduced into tumor cells through a recombinant adenovirus vector, 2003, pp.63, 4420~4425
103. Gabrilovich DI, "Myeloid-derived suppressor cells as regulators of the immune system", Nat Rev Immunol, 9, pp.162~174 (2009)[DOI]
104. Kittang AO, "Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome", OncoImmunology, 5, pp.e1062208~ (2015)
105. Chiu DK, "Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26", Hepatology, 64, pp.797~813 (2016)[DOI]

관련 논문AI추천